NCT05818163

Brief Summary

Using data from electroencephalogram (EEG) obtained through intraoperative depth of anesthesia monitoring devices, combined with clinical symptoms such as postoperative pain and delirium, investigate their correlation and verify whether intraoperative EEG spectral analysis can predict the occurrence of postoperative pain, nausea and vomiting, restlessness, or delirium in patients undergoing surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 5, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 18, 2023

Completed
13 days until next milestone

Study Start

First participant enrolled

May 1, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

April 18, 2023

Status Verified

April 1, 2023

Enrollment Period

7 months

First QC Date

April 5, 2023

Last Update Submit

April 5, 2023

Conditions

Keywords

electroencephalography spectral analysispostoperative complicationsanesthesia monitoring

Outcome Measures

Primary Outcomes (2)

  • pain in the postanesthesia care unit

    Visual Analog Scale (VAS) \> 3 in the postanesthesia care unit

    up to 2 hours, postanesthesia

  • agitation in the postanesthesia care unit

    Richmond Agitation-Sedation Scale (RASS)\>2 in the postanesthesia care unit

    up to 2 hours, postanesthesia

Secondary Outcomes (2)

  • delirium

    up to 2 days, postanesthesia

  • nausea and vomiting

    up to 1 day, postanesthesia

Study Arms (2)

with postoperative complications

Patients who experience postoperative complications after anesthesia, with symptoms such as pain, nausea and vomiting, delirium, and agitation.

Device: electroencephalography spectral analysis

without postoperative complications

Patients who do not experience postoperative complications after anesthesia, free from symptoms such as pain, nausea and vomiting, delirium, and agitation.

Device: electroencephalography spectral analysis

Interventions

Before inducing general anesthesia in the patient entering the operating room, an anesthesia depth monitoring patch is attached to the forehead, and EEG data during anesthesia is collected using the currently used anesthesia depth monitoring device. The EEG data is transformed into a frequency and energy distribution and density spectral array (DSA) graph using Fourier transform (FFT) for spectral analysis.

Also known as: density spectral array, patient state index (PSI)
with postoperative complicationswithout postoperative complications

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients aged 20 years or older who received general anesthesia within the National Taiwan University Hospital system.

You may qualify if:

  • Aged 20 years or older.
  • Patients who received general anesthesia within the our hospital system.

You may not qualify if:

  • Individuals with suspected infections, such as a fever higher than 38.3℃
  • Individuals with renal dysfunction, such as those with creatinine levels higher than 1.5 or those who require long-term dialysis
  • Individuals with cardiac dysfunction, such as those with NYHA class III or higher heart failure or coronary heart disease Individuals with neurological diseases, such as those with brain tumors, dementia, stroke, or epilepsy
  • Vulnerable populations, such as minors (under 20 years of age), pregnant women and fetuses, prisoners, adults who cannot give informed consent, individuals with disabilities, individuals with mental illness, residents of nursing homes or long-term care facilities, or those who may be subject to coercion or unable to make decisions freely.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University, Cancer Center

Taipei, 106, Taiwan

RECRUITING

MeSH Terms

Conditions

PainPostoperative Complications

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPathologic Processes

Central Study Contacts

Chung Chih Shih, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 5, 2023

First Posted

April 18, 2023

Study Start

May 1, 2023

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

April 18, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations